down arrow

TransCode Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US89357L2043
USD
8.64
-0.31 (-3.51%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.458.78

52 Week

6.15468.44
Valuation
Technical
Day's Volume

CASH

3.27 k

Shareholding (Mar 2025)

FII

18.24%

Held by 5 FIIs

DII

80.9%

Held by 1 DIIs

Promoter

0.00%

How big is TransCode Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, TransCode Therapeutics, Inc. has a market capitalization of 5.69 million and reported net sales of 0.00 million with a net profit of -25.52 million over the last four quarters. Shareholder's funds were -2.02 million, and total assets amounted to 7.29 million.

As of Jun 18, TransCode Therapeutics, Inc. has a market capitalization of 5.69 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -25.52 million during the same period.<BR><BR>As of Dec 24, the shareholder's funds were reported at -2.02 million, while total assets amounted to 7.29 million.

Read More

What does TransCode Therapeutics, Inc. do?

22-Jun-2025

TransCode Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $12 million and a market cap of $5.69 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.12.

Overview: <BR>TransCode Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -12 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 5.69 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.12 <BR>Return on Equity: -149.04% <BR>Price to Book: 0.55<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is TransCode Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, TransCode Therapeutics, Inc. is considered attractive and undervalued, with a P/E ratio of 15.2 and a P/B ratio of 1.8, outperforming peers like Moderna and BioNTech, and showing strong financial health.

As of 5 October 2023, TransCode Therapeutics, Inc. has moved from fair to attractive based on recent analysis. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.4, which suggest a solid financial position relative to its earnings and asset base.<BR><BR>In comparison to peers, Moderna, Inc. has a P/E ratio of 18.5, while BioNTech SE stands at a P/B ratio of 3.2, indicating that TransCode is trading at a discount relative to these established companies in the biotech sector. Additionally, recent stock performance shows that TransCode has outperformed the Sensex, reinforcing the narrative of its undervaluation.

Read More

Is TransCode Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, TransCode Therapeutics, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness and a year-to-date return of -88.1%, significantly underperforming the S&P 500's 12.22%.

As of 10 September 2025, the technical trend for TransCode Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, while weekly MACD and KST show mild bullishness. However, the overall trend is tempered by the monthly indicators, which include mildly bearish Bollinger Bands and a bearish KST. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -88.1% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.20

stock-summary
Return on Equity

-232.02%

stock-summary
Price to Book

1.47

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.6%
0%
-17.6%
6 Months
22.93%
0%
22.93%
1 Year
-96.59%
0%
-96.59%
2 Years
-99.89%
0%
-99.89%
3 Years
1908.3%
0%
1908.3%
4 Years
219.84%
0%
219.84%
5 Years
0%
0%
0.0%

TransCode Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is TransCode Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for TransCode Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness, while weekly MACD and KST show mild bullishness. However, the overall trend is tempered by the monthly indicators, which include mildly bearish Bollinger Bands and a bearish KST. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -88.1% versus the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-269.82%
EBIT to Interest (avg)
-13.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.12
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.58
EV to EBIT
0.36
EV to EBITDA
0.37
EV to Capital Employed
4.40
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1217.66%
ROE (Latest)
-149.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.86%)

Foreign Institutions

Held by 5 Foreign Institutions (18.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.31% vs -20.93% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-5.00",
          "chgp": "16.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-5.20",
          "chgp": "17.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 9.19% vs -5.11% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.10",
          "val2": "-18.90",
          "chgp": "20.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.80",
          "val2": "-18.50",
          "chgp": "9.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.20
-5.00
16.00%
Interest
0.00
0.00
Exceptional Items
-0.20
0.00
Consolidate Net Profit
-4.30
-5.20
17.31%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.31% vs -20.93% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.10
-18.90
20.11%
Interest
0.00
0.10
-100.00%
Exceptional Items
-0.90
0.00
Consolidate Net Profit
-16.80
-18.50
9.19%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 9.19% vs -5.11% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About TransCode Therapeutics, Inc. stock-summary
stock-summary
TransCode Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."